Related Experiment Videos
The benefit of abciximab in percutaneous coronary revascularization is not device-specific
D L Bhatt1, A M Lincoff, R M Califf
1Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA.
Insights
Abciximab reduces adverse outcomes like death and myocardial infarction (MI) after percutaneous coronary interventions, irrespective of the device used. This benefit was observed across various procedures without increasing bleeding risks.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Abciximab is an antiplatelet medication used during percutaneous coronary interventions (PCI).
- Its efficacy in reducing adverse events post-PCI is established, but its benefit across different interventional devices requires further clarification.
Purpose of the Study:
- To evaluate the comparative effectiveness of abciximab in reducing adverse outcomes across distinct interventional device strategies during PCI.
- To determine if the benefit of abciximab varies based on the specific device employed in coronary revascularization.
Main Methods:
- Pooled data from five placebo-controlled trials of abciximab in coronary intervention.
- Patients were stratified by intervention type: balloon angioplasty, elective stenting, bailout stenting, and directional coronary atherectomy.
- Cox proportional-hazards models were used to analyze 30-day death or myocardial infarction (MI) rates.
Main Results:
- Abciximab significantly reduced 30-day death or MI rates across all device groups (HR 0.55; p < 0.001).
- Hazard ratios for death or MI were 0.52 for balloon angioplasty, 0.51 for elective stenting, 0.38 for bailout stenting, and 0.38 for directional coronary atherectomy.
- No significant increase in major bleeding complications was observed with abciximab use, regardless of the device category.
Conclusions:
- Abciximab provides a consistent and significant reduction in death and MI after PCI, irrespective of the interventional device used.
- The drug is effective across balloon angioplasty, elective stenting, bailout stenting, and directional coronary atherectomy.
- The use of abciximab in PCI is associated with improved clinical outcomes without a significant increase in bleeding complications.
Abstract:
Abciximab has been shown to decrease adverse outcomes after percutaneous coronary interventions, but it is unclear whether this beneficial effect is more or less pronounced with specific devices. This study sought to determine the relative magnitude of the benefit of abciximab among different interventional devices. Data from the 5 placebo-controlled trials of abciximab during coronary intervention were pooled. Patients were divided into groups based on whether they received balloon angioplasty alone, elective stenting, bailout stenting, or directional coronary atherectomy. In the patients undergoing balloon angioplasty, the 30-day hazard ratio for death or myocardial infarction (MI) in the group randomized to abciximab versus the placebo-treated group was 0.52 (p <0.001), for elective stenting the hazard ratio was 0.51 (p <0.001), for bailout stenting the hazard ratio was 0.38 (p <0.001), and for directional coronary atherectomy the hazard ratio was 0.38 (p = 0.007). A Cox proportional-hazards model revealed that overall, the use of abciximab decreased the composite end point of 30-day death or MI rates (hazard ratio 0.55, 95% confidence interval 0.43 to 0.69, p <0. 001). However, bailout stenting and directional coronary atherectomy were associated with increased rates of death or MI compared with balloon angioplasty, as was elective stenting in women compared with men. There was no significant increase in major bleeding episodes associated with abciximab in any of the device categories. These findings from all the controlled coronary revascularization trials using abciximab demonstrate that a decrease in death and MI is achieved with abciximab regardless of the type of device used, without an increase in significant bleeding complications.